RENyTE is a human tissue allograft derived from the umbilical cord and is intended for homologous use to supplement or replace damaged or inadequate connective tissue.

The cushioning and structural support elements from the Wharton’s Jelly consist of a network of structural proteins, cytokines, chemokines, and growth factors. Wharton’s Jelly also has a much higher concentration of hyaluronic acid, cytokines, and growth factors when compared to Amniotic fluid, up to 50 times more. Hyaluronic acid is the key factor in the viscoelastic properties in synovial fluid and joints.


  • RENyTE is less invasive when compared to other forms of regenerative medicine such as bone marrow aspirate and adipose tissue extraction. This results in less pain and rehabilitation time for the patient.
  • Compared to amniotic fluid therapy, RENyTE contains higher concentrations of hyaluronic acid, peptides, and growth factors.
  • Higher concentrations of growth factors in RENyTE act as an anti-inflammatory and have been shown to prevent cell death.
  • RENyTE is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards. RENyTE is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

Potential Treatment Areas

  • Aesthetics
  • Back Pain
  • Cartilage Damage
  • Degenerated Joints
  • Joint Dysfunction
  • Knee Injuries
  • Ligament Tears
  • Meniscus Damage
  • Muscle Tears
  • Nerve Injury
  • Rotator Cuff Injury
  • Tendon Tears